PT806956E - Utilizacao de nucleosidos 5-substituidos para a inibicao de formacao de resistencia no tratamento com citostaticos - Google Patents

Utilizacao de nucleosidos 5-substituidos para a inibicao de formacao de resistencia no tratamento com citostaticos

Info

Publication number
PT806956E
PT806956E PT96901696T PT96901696T PT806956E PT 806956 E PT806956 E PT 806956E PT 96901696 T PT96901696 T PT 96901696T PT 96901696 T PT96901696 T PT 96901696T PT 806956 E PT806956 E PT 806956E
Authority
PT
Portugal
Prior art keywords
cytostatic
bvdu
cytostatic treatment
inhibition
resistance
Prior art date
Application number
PT96901696T
Other languages
English (en)
Portuguese (pt)
Inventor
Rudolf Fahrig
Angela Steinkamp-Zucht
Original Assignee
Resprotect Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545892A external-priority patent/DE19545892A1/de
Application filed by Resprotect Gmbh filed Critical Resprotect Gmbh
Publication of PT806956E publication Critical patent/PT806956E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PT96901696T 1995-02-01 1996-01-31 Utilizacao de nucleosidos 5-substituidos para a inibicao de formacao de resistencia no tratamento com citostaticos PT806956E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19503152 1995-02-01
DE19545892A DE19545892A1 (de) 1995-12-08 1995-12-08 Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU

Publications (1)

Publication Number Publication Date
PT806956E true PT806956E (pt) 2003-01-31

Family

ID=26012025

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96901696T PT806956E (pt) 1995-02-01 1996-01-31 Utilizacao de nucleosidos 5-substituidos para a inibicao de formacao de resistencia no tratamento com citostaticos

Country Status (12)

Country Link
US (1) US6589941B1 (de)
EP (1) EP0806956B1 (de)
JP (1) JPH11502515A (de)
KR (1) KR100330602B1 (de)
AT (1) ATE222765T1 (de)
BR (1) BR9607109A (de)
DE (1) DE59609590D1 (de)
DK (1) DK0806956T3 (de)
ES (1) ES2180730T3 (de)
NO (1) NO315258B1 (de)
PT (1) PT806956E (de)
WO (1) WO1996023506A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413881T1 (de) 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
DE19842578A1 (de) * 1998-09-17 2000-03-23 Max Delbrueck Centrum Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
AU774492B2 (en) 1999-07-22 2004-07-01 Celmed Oncology (Usa) Inc. Methods for treating therapy-resistant tumors
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
AU2451601A (en) * 1999-12-23 2001-07-03 Newbiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
EP1359921A4 (de) 2001-01-19 2006-09-06 Newbiotics Inc Verfahren zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
DE10313035A1 (de) * 2003-03-24 2004-10-07 Resprotect Gmbh Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen
US20060269596A1 (en) * 2005-01-12 2006-11-30 Gary Liversidge Controlled release compositions comprising an acylanilide
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090068286A1 (en) * 2007-09-11 2009-03-12 Resprotect, Gmbh Method of treating cancer by administration of 5-substituted nucleosides
EP2135601A1 (de) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilisierung amorpher Arzneimittel über schwammähnliche Trägermatrizen
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
EP2794630A4 (de) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituierte phosphorthioat-nukleotidanaloga
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069096A (en) * 1962-11-23 1967-05-17 Ile De Rech S Scient Et Ind So New organic derivatives of nucleotides and method for their manufacture
GB1473148A (de) * 1974-09-16 1977-05-11
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
NL8700366A (nl) * 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5831064A (en) 1996-07-25 1998-11-03 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents

Also Published As

Publication number Publication date
JPH11502515A (ja) 1999-03-02
KR100330602B1 (ko) 2002-08-22
NO973529L (no) 1997-10-01
EP0806956A1 (de) 1997-11-19
ES2180730T3 (es) 2003-02-16
US6589941B1 (en) 2003-07-08
NO315258B1 (no) 2003-08-11
DK0806956T3 (da) 2003-01-06
MX9705758A (es) 1997-10-31
NO973529D0 (no) 1997-07-31
ATE222765T1 (de) 2002-09-15
WO1996023506A1 (de) 1996-08-08
BR9607109A (pt) 1997-11-04
KR19980701862A (ko) 1998-06-25
DE59609590D1 (de) 2002-10-02
EP0806956B1 (de) 2002-08-28

Similar Documents

Publication Publication Date Title
PT806956E (pt) Utilizacao de nucleosidos 5-substituidos para a inibicao de formacao de resistencia no tratamento com citostaticos
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
EP2295063A8 (de) Zusammensetzungen und deren Verwendung zur Behandlung von Erkrankungen der Mitochondrien
DE3587434D1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
BR9904719A (pt) Composição para incrementar a permeabilidade de agentes tópicos à pele
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
MY119375A (en) Treatment of tinnitus using neuroprotective agents
WO2000002549A3 (en) Composition for and method of treating neurological disorders
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
CA2418167A1 (en) Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
PL368271A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
PT854724E (pt) Metodo de tratar a doenca navicular em cavalos
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
GR3034142T3 (en) Composition for the treatment or prevention of herpes
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
WO2001044270A3 (en) Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
BR0317511A (pt) Composição compreendendo reboxetina e um inibidor seletivo de ciclooxigenase-2 e kit